Skip to main content
. 2019 Mar 4;24(9):e930–e942. doi: 10.1634/theoncologist.2018-0411

Figure 4.

image

Pharmacokinetics of merestinib. (A): Pharmacokinetics following the first dose of merestinib on day 1 of cycle 1 in patients receiving enabled formulation. (B): Exposure to merestinib following first dose, AUC0–24. Note: Dose levels on the x‐axis are categorical, not continuous. The axis is not drawn to scale.

Abbreviation: AUC0–24, area under the concentration‐time curve over 24 hours.